drug_type
RELEVANT_DRUG
intervention_type
Drug (Antibody–Drug Conjugate)
drug_description
An intravenous antibody–drug conjugate (ADC) targeting a tumor-associated antigen. Following antigen binding and internalization, a cleavable linker releases a cytotoxic payload that kills tumor cells (via microtubule disruption and/or DNA damage); Fc-mediated immune effector functions may contribute. Dosed every 3 weeks.
nci_thesaurus_concept_id
C199292
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed topoisomerase inhibitor (TopoI), with potential antineoplastic activity. Upon administration of the anti-TROP-2/TopoI ADC MHB036C, the anti-TROP-2 antibody targets and binds to TROP-2 expressed on tumor cells. Upon binding, internalization and cleavage, TopoI is released, and inhibits DNA topoisomerase activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
TROP-2-targeted monoclonal antibody linked via a cleavable linker to a topoisomerase I inhibitor; after antigen binding and internalization, linker cleavage releases the payload to inhibit topoisomerase I, blocking DNA replication and inducing DNA damage, cell-cycle arrest, and apoptosis in TROP-2-expressing tumor cells; Fc-mediated effector functions may contribute.
drug_name
MHB036C
nct_id_drug_ref
NCT06373406